<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506009</url>
  </required_header>
  <id_info>
    <org_study_id>k(2017)29</org_study_id>
    <nct_id>NCT03506009</nct_id>
  </id_info>
  <brief_title>Argatroban Plus r-tPA for Posterior Circulation Infarction（AR-PCI）</brief_title>
  <official_title>Argatroban Plus R-tPA for Acute Posterior Circulation Infarction (AR-PCI): a Prospective, Random, Blinded Assessment of Outcome and Open Label Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui-Sheng Chen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of&#xD;
      morbidity, mortality and disability. A large number of studies have confirmed that the&#xD;
      thrombolytic therapy can effectively open blood vessels and improve the functional prognosis&#xD;
      of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment&#xD;
      to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients&#xD;
      receiving thrombolysis will have good prognosis, while a large number of patients will still&#xD;
      be disabled and even dead. How to improve the neurofunction prognosis of thrombolytic&#xD;
      patients has been a hot topic in the world.&#xD;
&#xD;
      Recent studies have found that the combined application of argatroban and rt-PA in the&#xD;
      treatment of acute anterior circulation infarction might improve the clinical prognosis and&#xD;
      not significantly increase bleeding. Some studies have reported that the combined application&#xD;
      of argatroban and rt-PA could improve the blood vessel opening rate, and prevent re-occlusion&#xD;
      after opening.&#xD;
&#xD;
      Based on the discussion, the present study is designed to explore the efficacy and safety of&#xD;
      argatroban plus rt-PA in the treatment of acute posterior circulation infarction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    it is very difficult to recruit qualified patients&#xD;
  </why_stopped>
  <start_date type="Actual">July 11, 2018</start_date>
  <completion_date type="Actual">November 13, 2018</completion_date>
  <primary_completion_date type="Actual">November 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of mRS (0-1）</measure>
    <time_frame>90±7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early neurological deterioration</measure>
    <time_frame>48 hours</time_frame>
    <description>4 or more increase in NIHSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of mRS (0-2）</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the occurence of stroke</measure>
    <time_frame>90±7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic intracranial hemorrhage</measure>
    <time_frame>36 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Argatroban, Rt-PA</condition>
  <arm_group>
    <arm_group_label>Argatroban combined with rt-PA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>rt-PA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Argatroban combined with rt-PA</intervention_name>
    <description>Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).</description>
    <arm_group_label>Argatroban combined with rt-PA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rt-PA</intervention_name>
    <description>Intravenous throbolysis with 0.9mg/kg rtPA.</description>
    <arm_group_label>rt-PA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-80 years old;&#xD;
&#xD;
          2. Diagnosis of posterior circulation ischemic stroke;&#xD;
&#xD;
          3. Time from onset to treatment ≤6 hours;&#xD;
&#xD;
          4. NIHSS: 4-25;&#xD;
&#xD;
          5. Signed informed consent by patient self or legally authorized representatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. mRS≥2;&#xD;
&#xD;
          2. History of stroke within 3 months;&#xD;
&#xD;
          3. History of intracranial hemorrhage;&#xD;
&#xD;
          4. Suspected subarachnoid hemorrhage;&#xD;
&#xD;
          5. Intracranial tumour, vascular malformation or arterial aneurysm;&#xD;
&#xD;
          6. Major surgery within 1 month;&#xD;
&#xD;
          7. Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg;&#xD;
&#xD;
          8. Platelet count &lt; 105/mm3;&#xD;
&#xD;
          9. Heparin therapy or oral anticoagulation therapy within 48 hours;&#xD;
&#xD;
         10. Abnormal APTT;&#xD;
&#xD;
         11. Thrombin or Xa factor inhibitor;&#xD;
&#xD;
         12. Severe disease with a life expectancy of less than 3 months;&#xD;
&#xD;
         13. Blood glucose &lt; 50 mg/dL (2.7mmol/L);&#xD;
&#xD;
         14. Patients who have received any other investigational drug or device within 3 months;&#xD;
&#xD;
         15. Pregnancy;&#xD;
&#xD;
         16. Researchers consider patients inappropriate to participate in the registry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>10016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>April 15, 2018</study_first_submitted>
  <study_first_submitted_qc>April 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>November 12, 2018</last_update_submitted>
  <last_update_submitted_qc>November 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Argatroban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

